Stem definition | Drug id | CAS RN |
---|---|---|
humanized origin | 5308 | 915810-67-2 |
Molecule | Description |
---|---|
Synonyms:
|
In patients with aTTP, levels of a substance called von Willebrand factor are increased. von Willebrand factor acts on platelets to cause them to stick together and form blood clots. Caplacizumab, the active substance in Cablivi, is a nanobody (a small antibody) which has been designed to attach to von Willebrand factor in a way that stops it acting on platelets. This reduces platelets sticking together and forming clots in blood vessels and, as a result, platelet levels in the blood rise because they are no longer taken up to form clots.
|
Dose | Unit | Route |
---|---|---|
10 | mg | P |
None
Date | Agency | Company | Orphan |
---|---|---|---|
Aug. 30, 2018 | EMA | ABLYNX NV | |
Feb. 6, 2019 | FDA | ABLYNX NV |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
ADAMTS13 activity decreased | 118.35 | 58.42 | 13 | 260 | 88 | 50604763 |
None
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
ADAMTS13 activity decreased | 141.70 | 51.66 | 16 | 328 | 145 | 64498243 |
ADAMTS13 activity abnormal | 89.23 | 51.66 | 8 | 336 | 0 | 64498388 |
Platelet count decreased | 56.64 | 51.66 | 24 | 320 | 167687 | 64330701 |
None
Source | Code | Description |
---|---|---|
ATC | B01AX07 | BLOOD AND BLOOD FORMING ORGANS ANTITHROMBOTIC AGENTS ANTITHROMBOTIC AGENTS Other antithrombotic agents |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Thrombotic thrombocytopenic purpura | indication | 78129009 | DOID:10772 |
None
None
None
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
von Willebrand factor | Unclassified | ANTIBODY BINDING | Kd | 8.51 | IUPHAR | DRUG LABEL |
ID | Source |
---|---|
2R27AB6766 | UNII |
C3713057 | UMLSCUI |
CHEMBL2109624 | ChEMBL_ID |
DB06081 | DRUGBANK_ID |
D11160 | KEGG_DRUG |
9123 | IUPHAR_LIGAND_ID |
2110604 | RXNORM |
36266 | MMSL |
d09171 | MMSL |
784411004 | SNOMEDCT_US |
789447000 | SNOMEDCT_US |
4038197 | VANDF |
4038198 | VANDF |
017896 | NDDF |
C585343 | MESH_SUPPLEMENTAL_RECORD_UI |
9511 | INN_ID |
None